KPKyle R. Padgett

Kyle R. Padgett

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kyle R. Padgett has a total of 255 co-authors. Here are the top co-authors by number of shared publications:

  • Nesrin Dogan

    Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, USA

    8 shared publications
  • Perry Johnson

    Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA

    6 shared publications
  • Alan Pollack

    Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1475 NW 12th Ave., Miami, FL 33136, United States

    5 shared publications
  • Radka Stoyanova

    Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA

    5 shared publications
  • John C. Ford

    Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, USA

    4 shared publications
  • Manuel Gonzalez-Brito

    University of Miami Miller School of Medicine

    4 shared publications

Latest Publications

  • Open Access

    Prognostic Value of Pre- and Post-Treatment PET-CT Metrics After Definitive Chemoradiation for Anal Canal Cancer

    by Raksha M. Narasimhan, Yuntao Wang, Justin T. Dreyer, Aren S. Saini, Armando Vera, Yunze Yang, Ifeanyichukwu C. Ogobuiro, Russ Kuker, Kyle R. Padgett, Aaron H. Wolfson

    Purpose: Although post-treatment FDG-PET/CT is frequently obtained following definitive chemoradiation (CRT) for locally advanced anal canal cancer (LAACC), its prognostic utility remains uncertain. We hypothesized that quantitative PET/CT metrics would be associated with overall survival (OS) and that pre-treatment metabolic parameters would provide greater prognostic information than post-treatment metabolic response. Methods: We conducted a retrospective cohort study of patients with LAACC who underwent definitive CRT and both pre-treatment and post-treatment fluorodeoxyglucose (FDG) PET/CT. Quantitative PET metrics were extracted, including mean SUL, total lesion glycolysis (TLG), metabolic tumor volume (MTV), maximum SUL, and peak SUL. OS was estimated using the Kaplan-Meier method. Associations between PET-derived variables and OS were evaluated using univariable Cox proportional hazards regression, with optimal cutoffs identified using maximally selected rank statistics (MaxStat). Results: Forty-five patients were included (median age 57.7 years), with post-treatment PET/CT performed at a median of 4.4 months following CRT. Lean body mass (HR 3.10, 95% CI 1.01–9.50; p = 0.049) and pre-treatment primary tumor mean SUL (HR 4.93, 95% CI 1.40–17.37; p = 0.013), size (HR 4.01, 95% CI 1.22–13.17; p = 0.022), TLG (HR 3.68, 95% CI 1.11–12.14; p = 0.033), and peak SUL (HR 3.31, 95% CI 1.02–10.72; p = 0.046) were associated with OS in exploratory univariable analyses. Post-treatment, higher weight (HR 4.94, 95% CI 1.06–22.96; p=0.041; cutoff 60.42 kg; N=45) and lean body mass (HR 4.82, 95% CI 1.06–21.90; p=0.042; cutoff 44.50 kg; N=44) were associated with worse OS. No post-treatment PET-derived metabolic parameters met the nominal threshold for statistical significance. Among patients with higher baseline metabolic activity, greater reduction in mean SUL following CRT demonstrated a nonsignificant trend toward improved OS. Conclusion: Pre-treatment FDG-PET/CT metabolic parameters demonstrated stronger associations with OS than post-treatment metabolic parameters in this exploratory cohort. Baseline tumor metabolic activity may provide useful prognostic information in patients with LAACC, warranting validation in larger prospective studies.

  • Open Access

    Assessment of Online Adaptive MRI-Guided Stereotactic Body Radiotherapy (SBRT) With an Integrated Boost to the Dominant Lesion in Prostate Cancer

    by Kyle R. Padgett, Jonathan Cabrera, Levent Sensoy, William Jin, Matthew C. Abramowitz, Matthew Studenski, Hayden Guerrero, Alberto de la Zerda, Siamak P. Nejad-Davarani, John C. Ford, et al.

    Purpose/objective Online adaptive radiotherapy (ART) with daily MR imaging can improve dosimetric accuracy by accounting for anatomical changes throughout the course of treatment. Existing daily ART prostate studies have diverse conclusions, but most of these studies do not include simultaneous integrated boosts (SIBs) to the dominant intraprostatic lesion, which has shown an increase in biochemical disease-free survival. The purpose of this study is to evaluate the potential dosimetric benefits of daily ART with SIB to the dominant intraprostatic lesion and other targets, as well as the potential sparing of organs-at-risk (OARs) for prostate cancer, and to compare these results with those reported in other published studies. Materials/methods Thirteen patients with prostate cancer treated with MR-guided stereotactic body radiotherapy (SBRT) were included in this study. The prescribed dose to the planning target volume (PTV) was 36.25 Gy in five fractions. The prescription to the intraprostatic boost to the gross tumor volume (GTV) ranged between 40 and 45 Gy. All SBRT fractions employed daily MR-guided setup, and OARs included the bladder, anorectum, bowel, femoral heads, and penile bulb. Daily MRIs and associated contours were used to create adapted treatment plans. For each simulated adapted fraction, the plan was re-optimized based on the contours from the daily setup MRI. Dosimetric metrics for non-adaptive fractions were simulated by re-calculating the dose on each daily setup MRI. PTV and GTV coverage and OAR constraints were used to compare non-adaptive and adaptive approaches. Results PTV coverage at the prescription dose level exceeded 90% in 35 out of 64 non-adapted treatment fractions (55%). Conversely, 29 fractions (45%) had less than 90% coverage, with 12 fractions (19%) showing coverage below 85%. The clinical target volume (CTV) coverage was greater than 95% in 52/64 fractions and was below 90% coverage in only 1/64 fractions (1.5%). GTV coverage at the boost dose level ranged from 55% to 100%, with 38 out of 74 fractions (51%) achieving 90% or greater coverage at the prescribed dose. A substantial number of fractions 27/74 (36%) had coverage below 85%, with a handful of fractions exhibiting less than 70% coverage, 5/74 fractions or 7%. All adapted fractions met prescribed coverage for the GTV, CTV, and PTV. Additionally, OAR constraint violations were evaluated and compared for the bladder and anorectum. Very few OAR constraints were exceeded in the non-adaptive setting, and none were exceeded in the adaptive setting. The anorectum dose constraint was exceeded in 22% of the non-adaptive fractions, while all adaptive fractions met the prescribed constraint. All non-adaptive and adaptive fractions met the prescribed bladder dose constraints; however, the adaptive fractions demonstrated some degree of bladder sparing compared to the non-adaptive fractions. Accumulated dose volume histograms were also generated for each patient to evaluate cumulative differences in target coverage and OAR sparing. Conclusion Online adaptive MR-guided SBRT for prostate cancer, utilizing daily plan re-optimization, resulted in improved target conformality, enhanced coverage, and increased OAR sparing compared to non-adaptive SBRT. The primary benefit observed was improved GTV coverage. Daily adaptive planning enables satisfactory GTV coverage without the need for added margins, while also providing better OAR sparing.


  • Potential to reduce margins and Shrink targets in patients with intact cervical cancer treated on An MRI guided radiation therapy (MRgRT) system

    by Lorraine Portelance, David Asher, Ricardo Llorente, Eric Mellon, Aaron Wolfson, Garrett Simpson, Jacqueline Baikovitz, Nesrin Dogan, Kyle R. Padgett


  • Open Access

    Single Fraction and Hypofractionated Radiation Cause Cochlear Damage, Hearing Loss, and Reduced Viability of Merlin-Deficient Schwann Cells

    by Christine T. Dinh, Si Chen, Aida Nourbakhsh, Kyle Padgett, Perry Johnson, Stefania Goncalves, Olena Bracho, Esperanza Bas, Jorge Bohorquez, Paula V. Monje, et al.

    Background: Vestibular schwannomas (VS) are benign intracranial tumors caused by loss of function of the merlin tumor suppressor. We tested three hypotheses related to radiation, hearing loss (HL), and VS cell survival: (1) radiation causes HL by injuring auditory hair cells (AHC), (2) fractionation reduces radiation-induced HL, and (3) single fraction and equivalent appropriately dosed multi-fractions are equally effective at controlling VS growth. We investigated the effects of single fraction and hypofractionated radiation on hearing thresholds in rats, cell death pathways in rat cochleae, and viability of human merlin-deficient Schwann cells (MD-SC). Methods: Adult rats received cochlear irradiation with single fraction (0 to 18 Gray [Gy]) or hypofractionated radiation. Auditory brainstem response (ABR) testing was performed for 24 weeks. AHC viabilities were determined using immunohistochemistry. Neonatal rat cochleae were harvested after irradiation, and gene- and cell-based assays were conducted. MD-SCs were irradiated, and viability assays and immunofluorescence for DNA damage and cell cycle markers were performed. Results: Radiation caused dose-dependent and progressive HL in rats and AHC losses by promoting expression of apoptosis-associated genes and proteins. When compared to 12 Gy single fraction, hypofractionation caused smaller ABR threshold and pure tone average shifts and was more effective at reducing MD-SC viability. Conclusions: Investigations into the mechanisms of radiation ototoxicity and VS radiobiology will help determine optimal radiation regimens and identify potential therapies to mitigate radiation-induced HL and improve VS tumor control.


  • Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT

    by Matthew T. Studenski, Rodrigo Delgadillo, Yihang Xu, Joseph Both, Kyle Padgett, Matthew Abramowitz, John C. Ford, Alan Dal Pra, Alan Pollack, Nesrin Dogan


  • Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers

    by Kyle R. Padgett, Garrett Simpson, David Asher, Lorraine Portelance, Elizabeth Bossart, Nesrin Dogan


  • Dichotomous Locomotor Recoveries Are Predicted by Acute Changes in Segmental Blood Flow after Thoracic Spinal Contusion Injuries in Pigs

    by Andrea Jimena Santamaria, Francisco D. Benavides, Kyle R. Padgett, Luis G. Guada, Yohjan Nunez-Gomez, Juan P. Solano, James D. Guest

    Neuroimaging facilitates the translation of animal pre-clinical research to human application. The large porcine spinal cord is useful for testing invasive interventions. Ideally, the safety and efficacy of a delayed intervention is tested in pigs that have recovered sufficiently after spinal cord injury (SCI) to allow either deterioration or improvement of function to be detected. We set out to create moderate severity T9 injuries in Yucatan minipigs by conducting a bridging study adapting methods previously developed in infant piglets. The injury severity was varied according to two pneumatic impactor parameters: the piston compression depth into tissue or the velocity. To stratify locomotor recovery, a 10-point scale used in prior piglet studies was redefined through longitudinal observations of spontaneous recovery. Using hindlimb body weight support to discriminate injury severity, we found that end-point recovery was strongly bimodal to either non-weight-bearing plegia with reciprocating leg movements (<5/10) or recovery of weight bearing that improved toward a ceiling effect (≥ 8/10). No intermediate recovery animals were observed at 2 months post-injury. The ability of intra-operative ultrasound and acute magnetic resonance imaging (MRI) to provide immediate predictive feedback regarding tissue and vascular changes following SCI was assessed. There was an inverse association between locomotor outcome and early gray matter hemorrhage on MRI and ultrasound. Epicenter blood flow following contusion predicted recovery or non-recovery of weight-bearing. The depth of the dorsal cerebrospinal fluid space, which varied between animals, influenced injury severity and confounded the results in this fixed-stroke paradigm.


  • Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer

    by Nancy El-Bared, Lorraine Portelance, Benjamin O. Spieler, Deukwoo Kwon, Kyle R. Padgett, Karen M. Brown, Eric A. Mellon


  • An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes

    by Radka Stoyanova, Felix Chinea, Deukwoo Kwon, Isildinha M. Reis, Yohann Tschudi, Nestor A. Parra, Adrian L. Breto, Kyle R. Padgett, Alan Dal Pra, Matthew C. Abramowitz, et al.


  • Dosimetric analysis of stereotactic body radiation therapy for pancreatic cancer using MR-guided Tri-60Co unit, MR-guided LINAC, and conventional LINAC-based plans

    by Stephen James Ramey, Kyle R. Padgett, Narottam Lamichhane, Hanmath J. Neboori, Deukwoo Kwon, Eric A. Mellon, Karen Brown, Melissa Duffy, James Victoria, Nesrin Dogan, et al.